Coagulation and Anticoagulation in Fontan Patients
- PMID: 35122939
- DOI: 10.1016/j.cjca.2022.01.028
Coagulation and Anticoagulation in Fontan Patients
Erratum in
- 
  
  Erratum to "Coagulation and Anticoagulation in Fontan Patients" [Can J Cardiol 38 (2022):1024-1035].Can J Cardiol. 2023 Nov;39(11):1731. doi: 10.1016/j.cjca.2023.09.001. Epub 2023 Sep 20. Can J Cardiol. 2023. PMID: 37741629 No abstract available.
Abstract
Patients with a Fontan circulation for single-ventricle physiology are at increased risk of developing thromboembolic events. Thromboembolic events can lead to failure of the Fontan circulation, chronic sequelae in case of stroke, and early mortality. Controversies exist regarding the substrates, risk factors, and optimal detection methods for thromboembolic events. Despite the major clinical implications, there is currently no consensus regarding the optimal antithrombotic therapy to prevent or treat thromboembolic events after the Fontan procedure. In this review we aimed to untangle the available literature regarding antithrombotic prophylaxis and treatment for pediatric and adult Fontan patients. A decision-tree algorithm for thromboprophylaxis in Fontan patients is proposed. Additionally, the current state of knowledge is reviewed with respect to the epidemiology, pathophysiology, and detection of thromboembolic events in Fontan patients, and important evidence gaps are highlighted.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        